Vifor Builds Its Kidney Disease Focus With $80m Angion Deal
Novel Drug Targets Two Kidney Injury Conditions
Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.
You may also be interested in...
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.
German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.